PL EN
RESEARCH PAPER
 
KEYWORDS
TOPICS
ABSTRACT
Introduction and objective:
Prophylactic examinations allow the reduction in morbidity from breast cancer and cervical cancer. The aim of the study was to estimate the impact of COVID-19 pandemic and the first months of restrictions in public life, introduced due to the risk of its outbreak, on the provision of services within cancer prevention programmes in Poland.

Material and methods:
The analysis was performed based on information concerning the number of mammography and cytology tests carried out as part of the breast cancer screening programme and cervical cancer screening programme. The study was conducted during January – May in 2020, and the same period in 2019 – as a basis for comparison. The data relate to three (out of sixteen) Polish Provinces: Katowice, Warsaw and Olsztyn.

Results:
At the time when pandemic restrictions were in force throughout the full months (April-May 2020) the number of mammography tests decreased by over 90% and the number of cytology tests decreased by more than 85%, compared to the same period in 2019. During the period of study, no statistically significant relationship was observed between a decrease in the number of screening tests and the number of recorded SARS-CoV-2 infections in individual provinces.

Conclusions:
Restrictions in public life introduced due to COVID-19 pandemic exerted a negative effect on breast cancer and cervical cancer prevention screening programmes. The reduction of attendance in screening tests for women in Poland was significant and, as a result, may affect individual prognosis of cancer patients due to the delay in detection of the disease

 
REFERENCES (35)
1.
Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badaw-czy. http://onkologia.org.pl/raport... (access: 2021.06.06).
 
2.
Sant M, Lopez MDCh, Agresti R, et al. The EUROCARE-5 Working Group, Survival of women with cancers of breast and genital organs in Europe 1999–2007: Results of the EUROCARE-5 study. Eur J Cancer. 2015; 51: 2191–2205.
 
3.
Wojtyniak B, Stokwiszewski J, Rubikowska B, et al. Długość życia i umieralność ludności Polski. In: Wojtyniak B, Goryński P, editors. Sytuacja zdrowotna ludności Polski i jej uwarunkowania. Warszawa: Narodowy Instytut Zdrowia Publicznego – Państwowy Zakład Higieny; 2018. p. 121.
 
4.
Biganzoli L, Cardoso F, Beishon M, et al. The requirements of a spe-cialist breast centre. Breast. 2020; 51: 65–84. https://doi.org/10.1016/j.brea....
 
5.
Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol. 2019; 30: 781–787. https://doi.org/10.1093/annonc....
 
6.
Ustawa z dnia 1 lipca 2005 r. o ustanowieniu programu wieloletniego «Narodowy program zwalczania chorób nowotworowych». DzU 2005 nr 143 poz. 1200 ze zm.
 
7.
Wasilewski P, Uczkiewicz J, Kwiatkowski K. Informacja o wynikach kontroli. Realizacja zadań „Narodowego Programu Zwalczania Chorób Nowotworowych”. Warszawa: Najwyższa Izba Kontroli; 2014.
 
8.
Uchwała nr 10 Rady Ministrów z dnia 4 lutego 2020 r. w sprawie przyjęcia programu wieloletniego pn. Narodowa Strategia Onkologiczna na lata 2020–2030. Monitor Polski. 18 lutego 2020 poz. 189.
 
9.
Rozporządzenie Ministra Zdrowia z dnia 13 marca 2020 r. w sprawie ogłoszenia na obszarze Rzeczypospolitej Polskiej stanu zagrożenia epidemicznego. DzU 2020 poz. 433.
 
10.
Rozporządzenie Ministra Zdrowia z dnia 20 marca 2020 r. w sprawie ogłoszenia na obszarze Rzeczypospolitej Polskiej stanu epidemii. DzU 2020 poz. 491.
 
11.
PTO. Zalecenia COVID-19. https://pto.med.pl/zalecenia-c... (access: 2021.06.06).
 
12.
Zalecenia i rekomendacje konsultanta krajowego dla radioterapii w warunkach epidemii COVID-19. https://ptro.org.pl/wgrane-pli... (access: 2021.06.06).
 
13.
Zalecenia Włoskich Towarzystw Onkologicznych dotyczące postępowania u chorych na nowotwory w czasie epidemii koronawirusa COVID-19. https://ligawalkizrakiem.pl/ak... (dostęp: 2021.06.06).
 
14.
Zawieszenie wykonywania badań mammograficznych w mammobusach. http://www.nfz-opole.pl/aktual... (access: 2021.06.06).
 
15.
Mammobusy wznowiły funkcjonowanie – harmonogram postoju mammobusów w Twojej okolicy. https://www.nfz.gov.pl/aktualn... (access: 2021.06.06).
 
16.
Sytuacja społeczno-gospodarcza województw Nr 1/2019. https://stat.gov.pl/obszary-te... (access: 2021.06.06).
 
17.
Sytuacja społeczno-gospodarcza województw Nr 1/2020. https://stat.gov.pl/obszary-te... (access: 2021.06.06).
 
18.
Chen RC, Haynes K, Du S, et al. Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic. JAMA Oncol. 2021; 29: e210884. https://doi.org/10.1001/jamaon....
 
19.
Tsai HY, Chang YL, Shen CT, et al. Effects of the COVID-19 pandemic on breast cancer screening in Taiwan. Breast. 2020; 54: 52–55. https://doi.org/10.1016/j.brea....
 
20.
de Pelsemaeker MC, Guiot Y, Vanderveken J, et al. The impact of the COVID-19 pandemic and the associated Belgian governmental measures on cancer screening, surgical pathology and cytopathology. Pathobiology. 2021; 88(1): 46–55. https://doi.org/10.1159/000509....
 
21.
Miller MJ, Xu L, Qin J, et al. Impact of COVID-19 on Cervical Cancer Screening Rates Among Women Aged 21–65 Years in a Large Integrated Health Care System – Southern California, January 1-September 30, 2019, and January 1-September 30, 2020. MMWR Morb Mortal Wkly Rep. 2021; 70: 109–113. https://dx.doi.org/10.15585/mm....
 
22.
Richards MA, Westcombe AM, Love SB, et al. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet. 1999; 353(9159): 1119–1126. https://doi.org/10.1016/s0140-....
 
23.
Lehman CD, Arao RF, Sprague BL, et al. National performance benchmarks for modern screening digital mammography: Update from the Breast Cancer Surveillance Consortium. Radiology. 2017; 283(1): 49–58. https://doi.org/10.1148/radiol....
 
24.
Rosenberg RD, Yankaskas BC, Abraham LA, et al. Performance benchmarks for screening mammography. Radiology. 2006; 241(1): 55–66. http://dx.doi.org/10.1148/radi....
 
25.
Grabler P, Sighoko D, Wang L, et al. Recall and cancer detection rates for screening mammography: Finding the Sweet Spot. Am J Roentg. 2017; 208: 208–213. https://www.ajronline.org/doi/....
 
26.
Smith-Bindman R, Chu PW, Miglioretti DL, et al. Comparison of screening mammography in the United States and the United Kingdom. JAMA. 2003; 290(16): 2129–2137. https://doi.org/10.1001/jama.2....
 
27.
Domingo L, Hofvind S, Hubbard RA, et al. Cross-national comparison of screening mammography accuracy measures in U.S., Norway, and Spain. Eur Radiol. 2016; 26: 2520–2528. https://doi.org/10.1007/s00330....
 
28.
Duijm LE, Louwman MW, Groenewoud JH, et al. Inter-observer variability in mammography screening and effect of type and number of readers on screening outcome. Br J Cancer. 2009; 100(6): 901–907. https://doi.org/10.1038/sj.bjc....
 
29.
Yong JH, Mainprize JG, Yaffe MJ, et al. The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada. J Med Screen. 2021; 28(2): 100–107. https://doi.org/10.1177/096914....
 
30.
Vanni G, Pellicciaro M, Materazzo M, et al. Lockdown of breast cancer screening for COVID-19: Possible scenario. In Vivo. 2020; 34(5): 3047–3053. https://doi.org/10.21873/inviv....
 
31.
Piekarzewska M, Wieczorkowski R, Zajenkowska-Kozłowska A. Stan zdrowia ludności Polski w 2014 r. Warszawa: Główny Urząd Statystyczny; 2016. https://stat.gov.pl/obszary-te... (access: 2021.06.06).
 
32.
Nowakowski A, Cybulski M, Śliwczyński A, et al. The implementation of an organised cervical screening programme in Poland: An analysis of the adherence to European guidelines. BMC Cancer. 2015; 15: 279. https://doi.org/10.1186/s12885....
 
33.
Lai A, Pasea L, Banerjee A, et al. Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency. medRxiv. 2020: 1–10. https://doi.org/10.1101/2020.0....
 
34.
Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020; 21(8): 1023–1034. https://doi.org/10.1016/S1470-....
 
35.
Sharpless NE. COVID-19 and cancer. Science. 2020; 368(6497): 1290. https://doi.org/10.1126/scienc....
 
eISSN:2084-4905
ISSN:2083-4543
Journals System - logo
Scroll to top